Joint protection in haemophilia

Haemophilia

Volumn 17, Issue SUPPL. 2, 2011, Pages 1-23

  Rodriguez Merchan, E C ^a,h   Jimenez Yuste, V ^a   Aznar, J A ^b   Hedner, U ^c   Knobe, K ^c   Lee, C A ^d   Ljung, R ^c   Querol, F ^b   Santagostino, E ^e   Valentino, L A ^f   Caffarini, A ^g  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

^c LUND UNIVERSITY   (Sweden)

^d UNIVERSITY OF LONDON   (United Kingdom)

^e UNIVERSITY OF MILAN   (Italy)

^f Rush Children's Hospital and Rush University Medical Center   (United States)

^g Medical Writer   (Spain)

^h AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

Author keywords

Haemarthrosis; Haemophilia; Inhibitor; Joint; Prophylaxis; Protection

Indexed keywords

BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9 CONCENTRATE; BUPIVACAINE; CODEINE; DIPYRONE; FENTANYL; MORPHINE; ONYX COPOLYMER; PARACETAMOL; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRAMADOL;

ACUTE KIDNEY FAILURE; ANALGESIA; ANGIOGRAPHY; ARTHRALGIA; ARTHROCENTESIS; ARTHROPATHY; ARTICLE; ARTIFICIAL EMBOLISM; CAST APPLICATION; CONFUSION; CRYOTHERAPY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; EARLY INTERVENTION; ECHOGRAPHY; FLEXION CONTRACTURE; GALLBLADDER DISEASE; GAS EMBOLISM; GOLD STANDARD; HEALTH CARE COST; HEMARTHROSIS; HEMOPHILIA A; HEMOPHILIA B; HUMAN; ILEUS; IMMOBILIZATION; IMMUNOLOGICAL TOLERANCE; JOINT ASPIRATION; JOINT DEGENERATION; LUNG EMBOLISM; NEURALGIA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARESTHESIA; PHYSIOTHERAPY; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY OF LIFE; SECONDARY PREVENTION; SEPSIS; SPLINT; SUBSTITUTION THERAPY; SYNOVITIS; TRACTION THERAPY; TREATMENT DURATION; TREATMENT INDICATION;

ARTHRALGIA; BLOOD COAGULATION FACTORS; HEMARTHROSIS; HEMOPHILIA A; HUMANS;

EID: 79961176998     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2011.02615.x     Document Type: Article

References (145)

1. Morfini M. Articular status of haemophilia patients with inhibitors. Haemophilia 2008; 14(Suppl. 6): 20-2.
2. Berntorp E. The treatment of haemophilia, including prophylaxis, constant infusion and DDAVP. Bailliere's Clin Haematol 1996; 9: 259-71.
3. Roosendaal G, Lafeber FPJG. Pathogenesis of heamophilic synovitis and arthropathy. In: Rodriguez-Merchan EC ed. The Haemophilic Joints: New Perspectives. Oxford: Wiley-Blackwell, 2003: 12-6.
4. Aronstam A, Rainsford SG, Painter MJ. Patterns of bleedings in adolescents with severe haemophilia A. Br Med J 1979; 1: 469-70.
5. Arnold WD, Hilgartner MW. Hemophilic arthropathy. Current concepts of pathogenesis and management. J Bone Joint Surg Am 1977; 59: 287-305.
6. Heim M, Rodriguez-Merchan EC, Horoszowski H. Current trends in hemophilia and other coagulation disorders. Orthopaedic complications and management. Intl J Pediatr Hematol Oncol 1994; 1: 545-51.
7. Merchan ECR, De Orbe A, Gago J. Ultrasound in the diagnosis of the early stages of hemophilic arthropathy of the knee. Acta Orthop Belg 1992; 58: 122-5.
8. Martin-Hervas C, Rodriguez-Merchan EC. Imaging of the hemophilic joint. In: Rodriguez-Merchan EC, Valentino LA, eds. Current and Future Issues in Hemophilia Care. London: Wiley-Blackwell, 2011: 121-6.
9. Klukowska A, Czyrny Z, Laguna P, Brzewski M, Serafin-Krol MA, Rokicka-Milewska R. Correlation between clinical, radiological and ultrasonographical image of knee joints in children with haemophilia. Haemophilia 2001; 7: 286-92.
10. Querol F, Cortina V, Cid AR, Haya S, Aznar JA. Clinical and ecographical control protocol of haemarthrosis in haemophilia patients with inhibitors: evaluation of the efficacy of recombinantfactor VIIa in the evolution process (EFFISEVEN protocol). Haemophilia 2008; 14(Suppl. 6): 36-44.
11. Pergantou H, Matsinos G, Papadopoulos A, Platokouki H, Aronis S. Comparative study of validity of clinical, X-ray and magnetic resonance imaging scores in evaluation and management of haemophilic arthropathy in children. Haemophilia 2006; 12: 241-7.
12. Funk MB, Schmidt H, Becker S et al. Modified magnetic resonance imaging score compared with orthopaedic and radiological scores for the evaluation of haemophilic arthropathy. Haemophilia 2002; 8: 98-103.
13. Nuss R, Kilcoyne RF, Geraghty S, Wiedel J, Manco-Johnson M. Utility of magnetic resonance imaging for management of hemophilic arthropathy in children. J Pediatr 1993; 123: 388-92.
14. Lundin B, Pettersson H, Ljung R. A new magnetic resonance imaging scoring method for assessment of haemophilic arthropathy. Haemophilia 2004; 10: 383-9.
15. Lundin B, Babyn P, Doria AS et al. Compatible scales for progressive and additive MRI assessments of haemophilic arthropathy. Haemophilia 2005; 11: 109-15.
16. Doria AS. State-of-the-art imaging techniques for the evaluation of haemophilic arthropathy: present and future. Haemophilia 2010; 16(Suppl. 5): 107-14.
17. Jansen NW, Roosendaal G, Lafeber FP. Understanding haemophilic arthropathy: an exploration of current open issues. Br J Haematol 2008; 14: 632-40.
18. Buzzard BM. Physiotherapy, rehabilitation and sports in countries with limited replacement coagulation factor supply. Haemophilia 2007; 13(Suppl. 2): 44-6.
19. Haegerstam GAT. Pathophysiology of bone pain. A review.. Acta Orthop Scand 2001; 72: 308-17.
20. Phillips WJ, Currier BL. Analgesic pharmacology: I. Neurophysiology. J Am Acad Orthop Surg 2004; 12: 213-20.
21. Phillips WJ, Currier BL. Analgesic pharmacology: II. Specific analgesics. J Am Acad Orthop Surg 2004; 12: 221-33.
22. Rodriguez-Merchan EC, Magallon M, Manso F, Martin-Villar J. Septic arthritis in HIV positive haemophiliacs. Four cases and a literature review. Int Orthop 1992; 16: 302-7.
23. Rodriguez-Merchan EC. Some recent developments regarding arthropathy and inhibitors in haemophilia. Haemophilia 2008; 14: 242-7.
24. Mauser-Bunschoten EP, Zijl JA, Mali W, van Rinsum AC, van den Berg HM, Roosendaal G. Successful treatment of severe bleeding in hemophilic target joints by selective angiographic embolization. Blood 2005; 105: 2654-7.
25. Klamroth R, Esseres E, Landgraf H, Wilaschek M, Oldenburg J. Successful angiographic embolization of recurrent elbow and knee joint bleeds in seven patients with severe haemophilia A. Haemophilia 2009; 15: 247-52.
26. Murugesan C, Saravanan S, Rajkumar J, Prasad J, Banakal S, MUralidhar K. Severe pulmonary oedema following therapeutic embolization with Onyx for cerebral arteriovenous malformation. Neuroradiology 2008; 50: 439-42.
27. Espandar R, Heidari P, Rodriguez-Merchan EC. The management of haemophilic pseudotumours with special emphasis on radiotherapy and arterial embolization. Haemophilia 2009; 15: 864-8.
28. Rodriguez-Merchan EC. Synoviorthesis in haemophilia. In: Lee CA, Berntorp E, Hoots WK, eds. Textbook of Haemophilia, 2nd edn. Oxford: Wiley-Blackwell, 2010: 182-6.
29. De la Corte-Rodriguez H, Rodriguez-Merchan EC, Jimenez-Yuste V. Radiosynovectomy in haemophilia: quantification of its effectiveness through the assessment of 10 articular parameters. J Thromb Haemost 2011; 9: 928-35.
30. De la Corte-Rodriguez H, Rodriguez-Merchan EC, Jimenez-Yuste V. Radiosynovectomy in patients with chronic haemophilic synovitis: when is more than one injection necessary?. Eur J Haematol 2011; 86: 430-5.
31. Stein H, Dickson RA. Reversed dynamic slings for knee flexion contractures in the hemophiliac. J Bone Joint Surg Am 1975; 57: 282-7.
32. Caviglia HA, Rodriguez-Merchan EC. An algorithm for the treatment of knee flexion contracture in haemophiliacs. In: Heijnen L ed. Recent Advances in Rehabilitation in Haemophili. East Sussex, UK: Medical Education Network, Hove, 1996: 39-45.
33. Roosendal G, Cansen NWD, Schutgens R, Lafeber FPJG. Haemophilic arthropathy: the importance of the earliest haemarthroses and consequences for treatment. Haemophilia 2008; 14(Suppl. 6): 4-10.
34. Lafeber FPGJ, Miossec P, Valentino LA. Physiopathology of haemophilic arthropaty. Haemophilia 2008; 14(Suppl. 4): 3-9.
35. Aznar JA, Lucia F, Abad-Franch L et al. Haemophilia in Spain. Haemophilia 2009; 15: 665-75.
36. Raffini L, Manno C. Modern management of haemophilic arthropathy. Br J Haematol 2007; 136: 777-87.
37. Stein H, Duthie RB. The pathogenesis of chronic haemophilic arthropathy. J Bone Joint Surg 1981; 63B: 601-9.
38. Roosendal G, Vianen ME, van den Berg HM, Lafeber FPJG, Bijlsma JW. Cartilage damage as a result of hemarthrosis in a human in vitro model. J Rheumatol 1997; 24: 1350-4.
39. Roosendal G, Vianen ME, Marx JJ, van den Berg HM, Lafeber FPJG, Bijlsma JW. Blood-induced joint damage: a human in vitro study. Arthritis Rheum 1999; 42: 1025-32.
40. Dabbagh AJ, Trenam CW, Morris CJ, Blake DR. Iron in joint inflammation. Ann Rheum Dis 1993; 52: 67-73.
41. Rodriguez-Merchan EC. Aspects of current management: orthopaedic surgery in haemophilia. Haemophilia 2011; Apr 27. doi:10.1111/j.1365-2516.2011.02544.x. (Epub ahead of print).
42. Leticia G, Piccione F, Redola C, Zummo G. Ultrastructural appearance of human synovial membrana in the reabsorption phase of acute haemarthrosis. Ital J Orthop Traumatol 1980; 6: 275-7.
43. Hermann G, Gilbert MS, Abdelwahab IF. Hemophilia: evaluation of musculoskeletal involvement with CT, sonography and MR imaging. Am J Roentgenol 1992; 158: 119-23.
44. Zukotynski K, Jarrin J, Babyn PS et al. Sonography for assessment of haemophilic arthropathy in children: a systematic protocol. Haemophilia 2007; 13: 293-304.
45. Querol F, Aparisi F, Beltran J, Cifirian C. Ecografía articular en hemofilia: ¿Una práctica para hematólogos? Haematologica (Spanish edition) 2009; 94: 175-81.
46. Aznar JA, Perez-Alenda S, Abad-Franch L, Cid AR, Haya S, Querol F. Intensive treatment of haemarthrosis in haemophilia: clinical and ultrasound management. Haemophilia 2010; 16(Suppl. 4): 21. Abstract 06P08).
47. Gilbert MS. Prophylaxis: musculoskeletal evaluation. Semin Hematol 1993; 30: 3-6.
48. Manco-Johnson M. Hemophilia management: optimizing treatment based on patient needs. Curr Opin Pediatr 2005; 17: 3-6.
49. Ahlberg Å. Hemophilia in Sweden, VII: incidence, treatment and prophylaxis of athropathy and other musculoskeletal manifestations of haemophilia A and B. Acta Orthop Scand 1965; 77(Supp. 1): 3-132.
50. Nilsson IM, Blomback M, Ahlberg A. Our experience in Sweden with prophylaxis on haemophilia. Proceedings of the 5th Congress of WFH, Montreal, No 34 New York: Karger, 1970; 111-24.
51. Nilsson IM, Hedner U, Ahlberg A. Haemophilia prophylaxis in. Acta Paediatr Scand 1976; 65: 129-35.
52. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years experience of prophylactic treatment in severe haemophilia A and B. J Int Med 1992; 232: 25-32.
53. Pettersson H, Ahlberg A, Nilsson IM. A radiologic classification of hemophilic arthropathy. Clin Orthop Relat Res 1980; 149: 153-9.
54. Pettersson H, Gilbert M. Diagnostic Imaging in Hemophilia: musculoskeletal and Other Hemorrhagic Complications. Berlin: Springer-Verlag, 1985: 56-65.
55. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994; 236: 391-9.
56. Fischer K, Van de Bom JG, Molho P et al. Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long term outcome. Haemophilia 2002; 8: 745-52.
57. Steen-Carlsson K, Hojgard S, Glomstein A et al. On-demand versus prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome. Haemophilia 2003; 9: 555-66.
58. Miners AH, Sabin CA, Tolley KH, Lee CA. Assessing the effectiveness and cost-effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrands disease. J Int Med 1998; 244: 515-22.
59. Miners AH, Sabin CA, Tolley KH, Lee CA. Primary prophylaxis for individuals with haemophilia: how many visits could treatment prevent? J Int Med 2000; 247: 493-9.
60. Miners AH, Sabin CA, Tolley KH, Jenkinson C, Kind P, Lee CA. Assessing health-related quality-of-life in individuals with haemophilia. Haemophilia 1999; 5: 378-85.
61. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent Joint Disease in Boys with Severe Hemophilia. N Engl J Med 2007; 357: 535-44.
62. Witmer C, Presley R, Kulkarni R, Michael Soucie J, Manno CS, Raffini L. Associations between intracranial haemorrhage and prescribed prophylaxis in a large cohort of haemophilia patients in the United States. Br J Haematol 2011; 152: 211-6.
63. Blanchette VS. Prophylaxis in the haemophilia population. Haemophilia 2010; 16: 181-8.
64. Stobart K, Iorio A, Wu JK. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with haemophilia A or B. Cochrane Database Syst Rev 2006; 2: 1-26.
65. Astermark J, Petrini P, Tengborn L, Schulman S, Ljung RCR, Berntorp E. Primary prophylaxis should be started at an early age but can be individualized. Br J Haematol 1999; 105: 1109-13.
66. Santagostino E, Marcuso ME. Venous access in haemophilic children: choice and management. Haemophilia 2010; 16: 20-4.
67. Yee TT, Beeton K, Harrington C, Miners A, Lee CA, Brown SA. Experience of prophylaxis treatment in children with severe haemophilia. Haemophilia 2002; 8: 76-82.
68. Valentino LA, Ewenstein B, Navickis RJ, Wilkes MM. Central venous devices in haemophilia. Haemophilia 2004; 10: 134-46.
69. Mancuso ME, Berardinelli L, Beretta C, Raiteri M, Pozzoli E, Santagostino E. Improved treatment feasibility in children with haemophilia using arteriovenous fistula: the results after seven years of follow-up. Haematologica 2009; 94: 687-92.
70. Ahnstrom J, Berntorp E, Lindvall K, Bjorkman S. A 6year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. Haemophilia 2004; 10: 689-97.
71. Collins PW, Blanchette VS, Fischer K et al. Breakthrough bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe haemophilia. J Thromb Haemost 2009; 7: 413-20.
72. Collins PW, Bjorkman S, Fischer K et al. Factor Viii requirement to maintain a target plasma level in the prophylactic treatment of severe haemophilia A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost 2010; 8: 269-75.
73. WHO Delivery of Treatment for Haemophilia: report of a Joint WHO/WFH/ISTH meeting 2002 WHO/HGN/WFH/ISTH/WG/02.6.
74. Batorova A, High KA, Gringeri A. Special lectures in haemophilia management. Haemophilia 2010; 16: 22-8.
75. Kreuz W, Escuriola-Ettingshausen C, Funk M, Schmidt H, Kornhuber B. When should prophylactic treatment in patients with haemophilia A and B start? - The German experience. Haemophilia 1998; 4: 413-7.
76. Soreff J, Blomback M. Arthropathy in children with severe hemophilia A. Acta Paediatr Scand 1980; 69: 667-73.
77. Ling M, Heysen JP, Duncan EM, Rodgers SE, Lloyd JV. High incidence of ankle arthropathy in mild and moderate haemophilia A. Thromb Haemost 2011; 105: 261-8.
78. Den Uijl IE, Fischer K, Van Der Bom JG, Grobbee DE, Rosendaal FR, Plug I. Clinical outcome of moderate haemophilia compared with severe and mild haemophilia. Haemophilia 2009; 15: 83-90.
79. Lundin B, Ljung R, Pettersson H. MRI scores of ankle joints in children with haemophilia - Comparison with clinical data. Haemophilia 2005; 11: 116-22.
80. Roosendaal G, van Rinsum AC, Vianen ME, van den Berg HM, Lafeber FP, Bijlsma JW. Haemophilic arthropathy resembles degenerative rather than inflammatory joint disease. Histopathology 1999; 34: 144-53.
81. Fischer K, van der Bom JG, Mauser-Bunschoten EP et al. The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. Blood 2002; 99: 2337-41.
82. Liesner RJ, Khair K, Hann IM. The impact of prophyactic treatment on children with severe haemophilia. Br J Haematol 1996; 92: 973-8.
83. Petrini P, Lindvall N, Egberg N, Blomback M. Prophylaxis with factor concentrates in preventing hemophilic arthropathy. Am J Pediatr Hematol Oncol 1991; 13: 280-7.
84. Collins PW, Fischer K, Morfini M, Blanchette VS, Bjorkman S. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia 2011; 17: 2-10.
85. Kreuz W, Escuriola Ettingshausen C, Funk M, Pons S, Schmidt H, Kornhuber B. [Prevention of joint damage in hemophilic children with early prophylaxis]. Orthopade 1999; 28: 341-6.
86. Fischer K, van der Bom JG, Mauser-Bunschoten EP et al. Endogenous clotting factor activity and long-term outcome in patients with moderate haemophilia. Thromb Haemost 2000; 84: 977-80.
87. Jansen NW, Roosendaal G, Bijlsma JW, Degroot J, Lafeber FP. Exposure of human cartilage tissue to low concentrations of blood for a short period of time leads to prolonged cartilage damage: an in vitro study. Arthritis Rheum 2007; 56: 199-207.
88. Jansen NW, Roosendaal G, Bijlsma JW, DeGroot J, Theobald M, Lafeber FP. Degenerated and healthy cartilage are equally vulnerable to blood-induced damage. Ann Rheum Dis 2008; 67: 1468-73.
89. Roosendaal G, Lafeber FP. Pathogenesis of haemophilic arthropathy. Haemophilia 2006; 12(Suppl. 3): 117-21.
90. Valentino LA. Blood-induced joint disease: the pathophysiology of hemophilic arthropathy. J Thromb Haemost 2010; 8: 1895-902.
91. Roosendaal G, Lafeber FP. Blood-induced joint damage in hemophilia. Semin Thromb Hemost 2003; 29: 37-42.
92. Mannucci PM. Ham-wasserman lecture: hemophilia and related bleeding disorders: a story of dismay and success. Hematology (Am Soc Hematol Educ Program) 2002; 1-9.
93. Pollmann H, Richter H, Ringkamp H, Jürgens H. When are children diagnosed as having severe haemophilia and when do they start to bleed? A 10-year single-centre PUP study. Eur J Pediatr 1999; 158(Suppl. 3): S166-70.
94. Hoots WK, Rodriguez N, Boggio L, Valentino LA. Pathogenesis of haemophilic synovitis: clinical aspects. Haemophilia 2007; 13(Suppl. 3): 4-9.
95. Valentino LA, Hakobyan N, Rodriguez N, Hoots WK. Pathogenesis of haemophilic synovitis: experimental studies on blood-induced joint damage. Haemophilia, 2007; 13(Suppl. 3): 10-3.
96. Valentino LA, Hakobyan N, Enockson C. Blood-induced joint disease: the confluence of dysregulated oncogenes, inflammatory signals, and angiogenic cues. Semin Hematol 2008; 45(Suppl. 1): S50-7.
97. Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH Jr. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet 1995; 10: 119-21.
98. Bi L, Sarkar R, Naas T et al. Further characterization of factor VIII-deficient mice created by gene targeting: RNA and protein studies. Blood 1996; 88: 3446-50.
99. Valentino LA, Hakobyan N, Kazarian T, Jabbar KJ, Jabbar AA. Experimental haemophilic synovitis: rationale and development of a murine model of human factor VIII deficiency. Haemophilia 2004; 10: 280-7.
100. Hakobyan N, Enockson C, Cole AA, Sumner DR, Valentino LA. Experimental haemophilic arthropathy in a mouse model of a massive haemarthrosis: gross, radiological and histological changes. Haemophilia 2008; 14: 804-9.
101. Valentino LA, Hakobyan N. Histological changes in murine haemophilic synovitis: a quantitative grading system to assess blood-induced synovitis. Haemophilia 2006; 12: 654-62.
102. Hakobyan N, Kazarian T, Valentino LA. Synovitis in a murine model of human factor VIII deficiency. Haemophilia 2005; 11: 227-32.
103. Valentino LA, Hakobyan N. Assessment of blood-induced arthritis causes friction. Haemophilia 2011; 17: e242-3.
104. Roosendaal G, Mauser-Bunschoten EP, De Kleijn P et al. Synovium in haemophilic arthropathy. Haemophilia 1998; 4: 502-5.
105. Hakobyan N, Kazarian T, Jabbar AA, Jabar KJ, Valentino LA. Pathobiology of hemophilic synovitis I: overexpression of mdm2 oncogene. Blood 2004; 104: 2060-4.
106. Wen FQ, Jabbar AA, Chen YX, Kazarian T, Patel DA, Valentino LA. c-myc proto-oncogene expression in hemophilic synovitis: in vitro studies of the effects of iron and ceramide. Blood 2002; 100: 912-6.
107. Rattray B, Nugent DJ, Young G. Rofecoxib as adjunctive therapy for haemophilic arthropathy. Haemophilia 2005; 11: 240-4.
108. Morfini M, Haya S, Tagariello H et al. European Study on Orthopaedic Status of haemophilia patients with inhibitors. Haemophilia 2007; 13: 606-12.
109. Scalone L, Mantovani G, Mannucci M, Gringeri A, COCIS Study Investigators. Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors. Haemophilia 2006; 12: 154-62.
110. Konkle BA, Ebbesen LS, Erhardtsen E et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007; 5: 1904-13.
111. Pro-PACT study. Retrospective prophylaxis patient case collection. ClinicalTrials.gov identifier NCT 00882778.
112. Leissinger CA, Berntorp E, Biasioli C et al. Prophylactic dosing of anti-inhibitor coagulant complex (FEIBA) reduces bleeding frequency in hemophilia A patients with inhibitors: results of the Pro-FEIBA study. Presented at the 52nd ASH, Orlando, FL, USA, December 4-7, 2010, Oral and Poster Abstract 720.
113. Jimenez-Yuste V, Alvarez MT, Martin-Salces N et al. Prophylaxis in 10 patients with severe haemophilia A and inhibitor: different approaches for different clinical situations. Haemophilia 2009; 15: 203-9.
114. DiMichele DM, Hoots K, Pipe SW, Rivard GE, Santagostino E. International workshop on immune tolerance induction: consensus recommendations. Haemophilia 2007; 13(Suppl. 1): 1-22.
115. Valentino LA. The benefits of prophylactic treatment with APCC in patients with haemophilia and high-titre inhibitors: a retrospective case series. Haemophilia 2009; 15: 733-42.
116. Young G, Auerswald G, Jimenez-Yuste V et al. When should prophylaxis therapy in inhibitor patients be considered?. Haemophilia 2011. March 21. doi: 10.1111/j.1365-2516.2011.02494.x. (Epub ahead of print).
117. Santagostino E, Morfini M, Auerswald GKH et al. Paediatric haemophilia with inhibitors: existing management options, treatment gaps and unmet need. Haemophilia 2009; 15: 983-9.
118. ENJOIH Study. European initiative to prevent joint damage in haemophilia children with inhibitors (ENJOIH) - A prospective study. ClinicalTrials.gov identifier NCT 01105546.
119. Löfqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients - A long-term follow-up. J Intern Med 1997; 241: 395-400.
120. Morfini M, Auerswald G, Kobelt RA et al. Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres. Haemophilia 2007; 13: 502-7.
121. Young G, McDaniel M, Nugent DJ. Prophylactic recombinant factor VIIa in haemophilia patients with inhibitors. Haemophilia 2005; 11: 203-7.
122. Siegmund B, Richter H, Pollman H. Prophytlactic treatment with Feiba of a haemophilia A patient with inhibitor: what are the costs, what are the benefits? Haemophilia 2005; 11: 638-41.
123. Hedner U. Factor VIIa and its potential therapeutic use in bleeding-associated pathologies. J Thromb Haemost 2008; 100: 557-62.
124. Allen GA, Wolberg AS, Oliver JA, Hoffman M, Roberts HR, Monroe DM. Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system. J Thromb Haemost 2004; 2: 402-13.
125. He S, Blombäck M, Jacobsson Ekman G, Hedner U. The role of recombinant factor VIIa (rFVIIa) in fibrin structure in the absence of FVIII/FIX. J Thromb Haemost 2003; 1: 1215-9.
126. Smith MP, Ludlam CA, Collins PW et al. Elective surgery on factor VIII inhibitor patients using continuous infusion of recombinant activated factor VII. J Thromb Haemost 2001; 86: 949-53.
127. Ludlam CA, Smith MP, Morfini M, Gringeri A, Santagostino E, Savidge GF. A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation. Br J Haematol 2003; 120: 808-13.
128. Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. Prospective, randomized trial of two doses of rFVIIa (rFVIIa) in haemophilia patients with inhibitors undergoing surgery. J Thromb Haemost 1998; 89: 773-8.
129. Bauer KA, Kass BI, ten Cate H, Bednarek MA, Hawiger JJ, Rosenberg RD. Detection of factor X activation in humans. Blood 1989; 74: 2007-15.
130. Bauer KA, Kass BI, ten Cate H, Hawiger JJ, Rosenberg RD. Factor IX is activated in vivo by the tissue factor mechanism. Blood 1990; 76: 731-6.
131. Weiss HJ, Lages B. Evidence for tissue factor-dependent activation of the classic extrinsic coagulation mechanism in blood obtained from bleeding time wounds. Blood 1988; 71: 629-35.
132. Le DT, Borgs P, Toneff TW, Witte MH, Rapaport SI. Hemostatic factors in rabbit limb lymph: relationship to mechanisms regulating extravascular coagulation. Am J Physiol 1998; 274: H769-76.
133. Bergström K, Werner B. Proteins in human thoracic duct lymph. Studies on the distribution of some proteins between lymph and blood. Acta Chir Scand 1966; 131: 413-22.
134. Blomstrand R, Nilsson IM, Dahlbäck O. Coagulation studies on human thoracic duct lymph. Scand J Clin Lab Invest 1963; 15: 248-54.
135. Brinkhous KM, Walker SA. Prthrombin and fibrinogen in lymph. Am J Physiol 1941; 132: 666-9.
136. Chrobak L, Bartos V, Brzek V, Hnizdova D. Coagulation properties of human thoracic duct lymph. Am J Med Sci 1967; 253: 69-75.
137. Miller GJ, Howarth DI, Attfield JC et al. Haemostatic factors in human peripheral afferent lymph. J Thromb Haemost 2000; 83: 427-32.
138. Chang P, Aronson DL, Borenstein DG, Kessler CM. Coagulant proteins and thrombin generation in synovial fluid: a model for extravascular coagulation. Am J Hematol 1995; 50: 79-83.
139. Kushner I, Somerville JA. Permeability of human synovial membrane to plasma proteins. Relationship to molecular size and inflammation. Arhtr Rheum 1971; 14: 560-70.
140. Wester J, Sixma JJ, Geuze JJ, van der Veen J. Morphology of the early hemostasis in human skin wounds. Lab Invest 1978; 39: 298-311.
141. Hoffman M, Harger A, Lenkowski A, Hedner U, Roberts HR, Monroe DM. Cutaneous wound healing is impaired in hemophilia B. Blood 2006; 108: 3053-60.
142. Weiss HJ, Turitto VT, Baumgartner HR. Role of shear rate and platelets in promoting fibrin formation on rabbit subendothelium. J Clin Invest 1986; 78: 1072-82.
143. Gopalakrishnan R, Hedner U, Ghosh S et al. Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa). J Thromb Haemost 2010; 8: 301-10.
144. Mandal S, Pendurthi UR, Rao LVM. Cellular localization and trafficking of tissue factor in fibroblasts. Blood 2006; 107: 4746-53.
145. Rapaport SI, Rao LVM. Initiation and regulation of tissue factor-dependent blood coagulation. Art Thromb 1992; 12: 1111-21.